Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06245746 | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | recruiting | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04513639 | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | recruiting | Phase 2 / Phase 3 | 176 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 |
| clinicaltrials |
| NCT05828459 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | recruiting | Phase 1 | 150 | Onward TherapeuticsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06758375 | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients | recruiting | Phase 2 | 10 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06885476 | Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients | recruiting | N/A | 22 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06886074 | Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL | recruiting | Phase 2 | 30 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06886425 | Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies(CDA-AML-MDS) | recruiting | N/A | 70 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01210274 | Characterization of the Mechanisms of Resistance to Azacitidine | recruiting | — | 250 | Centre Hospitalier Universitaire de NiceOTHER | 2 | Mar 19, 2025 | clinicaltrials |
| NCT06764017 | CHiR Therapy for Elderly DLBCL Intolerant to Chemo | recruiting | Phase 2 | 30 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883604 | Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin(PRO-Hodgkin) | recruiting | N/A | 75 | Uppsala University HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06758037 | Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy(HiR+X) | recruiting | Phase 2 | 50 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 18, 2025 | clinicaltrials |
| NCT05475600 | APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU(APAER_H) | recruiting | N/A | 90 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06879379 | KPD Consolidation After ASCT in NDMM Patients | recruiting | Phase 2 / Phase 3 | 202 | Peking University People's HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04867915 | Study on the Diagnosis and Management of CLL in Italy by GIMEMA | recruiting | — | 12,500 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06028087 | Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment | recruiting | — | 736 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04314219 | Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients(PTCy-PMAT) | recruiting | Phase 3 | 264 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06874257 | Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade | recruiting | — | 20 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05595447 | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 / Phase 3 | 20 | Hospital Regional de Alta Especialidad del BajioOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06291428 | Raman Spectroscopy Compared to Flow Cytometry | recruiting | — | 50 | Hospital Regional de Alta Especialidad del BajioOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06581081 | Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia | recruiting | N/A | 130 | Peking University People's HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06201247 | Off-the-shelf CD123 CAR-NK for R/R AML | recruiting | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05190471 | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 48 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06613217 | Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | Pacylex PharmaceuticalsINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06866873 | CD-19 CAR-T Cell for Pediatric ALL or Lymphoma | recruiting | N/A | 18 | Hong Kong Children's HospitalOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT02781883 | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | recruiting | Phase 2 | 108 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863584 | SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial | recruiting | Phase 2 | 41 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06060782 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine(TCCA) | recruiting | Phase 1 | 28 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05472558 | Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | recruiting | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT06845592 | Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia(SHARP) | recruiting | N/A | 51 | University Of PerugiaOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06834412 | A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging | recruiting | N/A | 120 | Xijing HospitalOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06045819 | Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX) | recruiting | — | 100 | University Hospital, CaenOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06170489 | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) | recruiting | Phase 3 | 185 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06851702 | Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors(Endemato) | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06848569 | Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study | recruiting | Phase 2 | 73 | Sun Yat-sen UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06850285 | CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma | recruiting | N/A | 15 | Shanxi Bethune HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06846905 | Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.(AmbuSpé) | recruiting | — | 40 | University Hospital, ToulouseOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06743945 | POLA-R-CHP in the First-line Treatment of Transformed DLBCL | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06835140 | CD123-CD16-NK Cells Immunotherapy for AML(CD123-CD16-NK) | recruiting | Phase 1 | 9 | Chunji GaoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06484816 | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06651866 | Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06737523 | Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML | recruiting | Phase 1 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788639 | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788652 | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06794268 | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 21, 2025source: clinicaltrials